
    
      Utilization of the EndoBarrier Gastrointestinal Liner in obese subjects with T2DM
      demonstrated an acceptable safety profile with clinically significant improvements in
      glycemic control and body weight when compared to a similar diet controlled group of
      subjects.
    
  